An interventional study of High-intensity transcranial alternating current stimulation (Hi-tACS) and Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS) in Schizophrenia; Negative Type and Transcranial Alternating Current Stimulation, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Schizophrenia by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Schizophrenia · Shanghai Mental Health Center.
Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, this one is the 28th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2024, is one of 35 with no phase, reaches primary completion later than 1 of the 14 other live ones, and was the 52nd registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →15 of the 61 studies in Schizophrenia by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–45
Shanghai Mental Health Center · Sites in China
Ages 18–45
Shanghai Mental Health Center · Sites in China
Ages 13–55
Shanghai Mental Health Center · Sites in China
Ages 18+
Shanghai Mental Health Center · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 4 · Phase 4 8
First in 2008; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 67 across the 50 interventional studies, 480 across the 11 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
5 of the studies in Schizophrenia by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT06802939Shanghai Mental Health CenterRTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography | 2026-12-10 |
| NCT07767526Shanghai Mental Health CenterXingqi Daozhi Decoction for Antipsychotic-Induced Constipation | 2027-06-01 |
| NCT06904092Shanghai Mental Health CenterEfficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit | 2027-10-31 |
| NCT05159349Shanghai Mental Health CenterMental Health During the Whole Life Cycle of Community Patients With Schizophrenia | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia.
Schizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks.
Negative symptoms, cognitive functioning, social functioning, and quality of life of intervention group and control group were assessed and compared between the two groups at baseline, 2 weeks, and 3 months post-intervention.
Objective: To investigate the therapeutic effects and short-term and long-term efficacy of high-intensity transcranial alternating current stimulation (Hi-tACS) on negative symptoms of schizophrenia.
Methods: A randomized controlled design was used, 60 schizophrenic patients who met the enrollment criteria were randomly assigned to either the Hi-tACS intervention group or the sham stimulation control group. Both groups continued their regular medication regimen. The intervention group received continuous current stimulation, while the control group received only 40 seconds of current stimulation per session. The treatment was administered twice daily (morning and afternoon) from Monday to Friday for 2 weeks, with each session lasting 40 minutes, for a total of 20 sessions. Negative symptoms, cognitive function, social function, and quality of life were assessed at baseline, 2 weeks, and 3 months post-intervention.
The primary outcome will be clinical symptoms, the secondary outcome will be the social function and quality of life, and the process measures included social cognition and neurocognition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On the basis of maintaining regular medication, the intervention group received continuous Hi-tACS stimulation. The intervention was administered twice daily, in the morning and afternoon, from Monday to Friday for 2 weeks, with each session lasting 40 minutes, totaling 20 sessions.
Device: High-intensity transcranial alternating current stimulation (Hi-tACS)
On the basis of maintaining regular medication, the control group received sham Hi-tACS stimulation, with each stimulation session lasting only 40 seconds. The intervention was administered twice daily, in the morning and afternoon, from Monday to Friday for 2 weeks, with each session lasting 40 minutes, totaling 20 sessions.
Device: Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS)
The equipment used is the transcranial microcurrent stimulator (Nexalin ADI), operated by trained therapists following standardized instructions. Three Nexalin conductive electrodes are placed on the patient's head. A 4.45×9.53 cm electrode is placed on the forehead, corresponding to the Fpz region of the 10/20 international standard electrode placement system. Two 3.18×3.81 cm electrodes are placed on the bilateral dorsolateral prefrontal cortex, corresponding to the F3 and F4 regions of the international standard electrode placement system. The stimulation frequency is 77.5 Hz, and the current intensity is 15 mA.
A sham device looks exactly the same as Nexalin ADI is used.
Change in negative symptoms of schizophrenia
The primary efficacy evaluation measure is the Positive and Negative Syndrome Scale (PANSS), with statistical parameters including the PANSS total score and the negative subscale score. These scores reflect the severity of schizophrenia symptoms, with higher total or subscale scores indicate more severe symptoms. A decrease in scores after the intervention indicates symptom reduction and effective intervention.
Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)
Change in sleep quality of clinical symptom
The sleep quality assessment measure is Pittsburgh Sleep Quality Index (PSQI). The PSQI is a widely used self-report questionnaire designed to assess sleep quality over a one-month period. The PSQI consists of 19 items, which are grouped into seven components. Each component is scored on a scale from 0 to 3, with higher scores indicating worse sleep quality. The total score ranges from 0 to 21, and a higher total score suggests poorer overall sleep quality. A decrease in the total score after the intervention suggests an improvement in sleep quality.
Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)
Change in depression of clinical symptom
The depression assessment measure is Hamilton Depression Rating Scale (HAMD). The HAMD is a widely used tool for assessing the severity of depression in individuals. The HAMD consists of 17 items. Each item is rated on a scale ranging from 0 to 4 or 0 to 2, with higher scores indicating more severe symptoms. A decrease in the total score after the intervention suggests an improvement in depression.
Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)
Change in anxiety of clinical symptom
The anxiety assessment measure is Hamilton Anxiety Scale (HAMA). The HAMA is a 14-item scale designed to assess the severity of anxiety symptoms in individuals. The total score ranges from 0 to 56, with higher scores indicating greater anxiety severity. A decrease in the total score after the intervention suggests an improvement in anxiety.
Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)
Change in theory of mind of social cognition
The theory of mind assessment measure is faux pas recognition (FPT). The FPT examines the patient's recognition of the faux pas situation of the speaker. Higher total scores on the FTP indicate a better ability to recognize and understand faux pas, as well as stronger empathetic skills. An increase in the total score after the intervention suggests an improvement in theory of mind and social cognition.
Time frame: change from baseline (W0) to 3 months after intervention (M3)
Change in emotion perception of social cognition
The emotion perception assessment measure is Face Emotion Identification Task (FEIT). The FEIT assesses the ability to perceive emotions. The score ranges from 0 to 30, with higher scores indicating better emotion perception. An increase in the total score after the intervention suggests an improvement in emotion perception.
Time frame: change from baseline (W0) to 3 months after intervention (M3)
Change in coping styles of social cognition
The coping styles assessment measure is Simplified Coping Style Questionnaire (SCSQ). The SCSQ assesses the coping styles of individuals when facing setbacks. The overall coping style score is typically calculated as the difference between the positive coping score and the negative coping score. A higher overall score suggests a more proactive and positive coping style. An increase in the total score after the intervention suggests an improvement in positive coping style.
Time frame: change from baseline (W0) to 3 months after intervention (M3)
Change in attributional styles of social cognition
The attributional styles assessment measure is Attributional Style Questionnaire (ASQ). The ASQ assesses attributional styles. Each cause of 12 events was rated according to locus of control (internal vs. external), stability, and globality, with higher scores indicating greater attractiveness on each dimension and a score of 4 indicating a neutral response. An increase in internal, stable, and global dimensions for positive events and a decrease in these dimensions for negative events after the intervention suggests an improvement in attributional styles.
Time frame: change from baseline (W0) to 3 months after intervention (M3)
Change in neuropsychological status of cognitive function
The neuropsychological status of cognitive function assessment measure is the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS is widely used in clinical settings to detect cognitive impairments and track cognitive changes over time. It consists of 12 subtests that assess five primary cognitive domains: immediate memory, visuospatial/constructional skills, attention, language and delayed memory. The total RBANS score is derived by summing the five index scores and then converting this sum to a total scale score using the provided normative tables. The total scale score ranges from 40 to 160, with higher scores indicating better cognitive function. An increase in the total score after the intervention suggests an improvement in neuropsychological status of cognitive function.
Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)
Change in EEG data of cognitive function
The electroencephalogram (EEG) data of cognitive function is P300. The P300 has been widely used in research and clinical settings to assess cognitive function. It is characterized by a positive deflection in the EEG signal that typically occurs approximately 300 milliseconds after the presentation of a target stimulus. The P300 is typically elicited using an oddball paradigm, where infrequent target stimuli are interspersed among more frequent non-target stimuli. To measure the P300, EEG data are collected using a set of electrodes placed on the scalp according to the international 10-20 system. The data are then pre-processed to remove artifacts and segmented into epochs around the stimulus onset. The average ERP is calculated for target and non-target stimuli separately, and the P300 is identified within the 250-500 ms time window.
Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)
Change in social function
The social function assessment measure is the Personal and Social Performance scale (PSP). The PSP is a widely used observer-rated scale for assessing patients' social functioning. The scale primarily assesses four areas of functioning in patients: useful activities in society, personal and social relationships, self-care and disruptive and aggressive behaviors. After scoring each of the four areas separately, a total score is determined according to the scoring standards. The total score ranges from 0 to 100 points and is divided into 10 levels, with higher scores reflecting better social function and interpersonal relationships. An increase in post-intervention scores indicates an improvement in social function.
Time frame: change from baseline (W0) to 3 months after intervention (M3)
Change in quality of life
The quality of life assessment measure is the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 scale is used to assess patients' health-related quality of life. It comprises 8 subscales with a total of 36 items, covering both physical and mental health aspects. The raw scores of each subscale are converted into standard scores ranging from 0 to 100, with higher scores indicating better quality of life in that particular domain. An increase in post-intervention scores suggests an improvement in quality of life.
Time frame: change from baseline (W0) to 3 months after intervention (M3)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Nov 2025, 17 months after the start.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 17 months is below that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →